Investor Relations

Corporate Profile

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).

Change

Volume

52 Week High

52 Week Low

Oct 26, 2020 6:06 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020

October 26, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 26, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases today announced that data from the Company’s maralixibat studies will be

Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States

October 15, 2020

Agreement outlines commercialization and distribution services to support patients diagnosed with Alagille syndrome FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 15, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 13, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 13, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that on October 9, 2020 , the

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 11, 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that on September 10, 2020 ,

Events

Cantor Fitzgerald Virtual Global Healthcare Conference

Sep 17, 2020 at 9:20 AM EDT

H.C. Wainwright & Co. 22nd Annual Global Investment Conference

Sep 14, 2020 at 9:30 AM EDT

EASL International Liver Congress 2020

Aug 27 - Aug 29, 2020

Investor Relations

Investor Relations

Corporate Profile

Header Menu